Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Bladder Urothelial Carcinoma”

30 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 30 results

Testing effectiveness (Phase 2)Study completedNCT00077688
What this trial is testing

TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium

Who this might be right for
Bladder NeoplasmsUreteral NeoplasmsUrethral Neoplasms+1 more
Achieve Life Sciences 44
Testing effectiveness (Phase 2)WithdrawnNCT03935347
What this trial is testing

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Who this might be right for
Metastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis Urothelial CarcinomaMetastatic Ureter Urothelial Carcinoma+3 more
Roswell Park Cancer Institute
Testing effectiveness (Phase 2)Looking for participantsNCT05267626
What this trial is testing

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Who this might be right for
Advanced Solid TumorMetastatic CancerCutaneous Melanoma+1 more
Aulos Bioscience, Inc. 159
Testing effectiveness (Phase 2)Active Not RecruitingNCT03601455
What this trial is testing

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Who this might be right for
Bladder Urothelial CarcinomaStage IV Bladder Cancer AJCC v8Stage IVA Bladder Cancer AJCC v8+1 more
Jonsson Comprehensive Cancer Center 13
Early research (Phase 1)Active Not RecruitingNCT03236935
What this trial is testing

Phase Ib of L-NMMA and Pembrolizumab

Who this might be right for
Non-Small Cell Lung CancerMalignant MelanomaHead and Neck Squamous Cell Carcinoma+3 more
The Methodist Hospital Research Institute 12
Early research (Phase 1)Looking for participantsNCT04878029
What this trial is testing

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Who this might be right for
Infiltrating Bladder Urothelial Carcinoma With Squamous DifferentiationLocally Advanced Urothelial CarcinomaMetastatic Urothelial Carcinoma+1 more
Emory University 32
Early research (Phase 1)Active Not RecruitingNCT06714617
What this trial is testing

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Who this might be right for
Breast Cancer Stage IIIHER2-positive Metastatic Breast CancerUnresectable Breast Carcinoma+11 more
SystImmune Inc. 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT00365157
What this trial is testing

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

Who this might be right for
Advanced Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Urothelial Carcinoma+4 more
National Cancer Institute (NCI) 132
Testing effectiveness (Phase 2)WithdrawnNCT06424717
What this trial is testing

Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)

Who this might be right for
Urothelial Carcinoma
EMD Serono Research & Development Institute, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT04879329
What this trial is testing

Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Who this might be right for
Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer 372
Not applicableStudy completedNCT05902494
What this trial is testing

HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

Who this might be right for
Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer 389
Testing effectiveness (Phase 2)Study completedNCT03513952
What this trial is testing

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Who this might be right for
Advanced Bladder Urothelial CarcinomaAdvanced Ureter Urothelial CarcinomaMetastatic Bladder Urothelial Carcinoma+21 more
National Cancer Institute (NCI) 47
Testing effectiveness (Phase 2)UnknownNCT01118039
What this trial is testing

Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
Hospital del Mar 41
Large-scale testing (Phase 3)Not Yet RecruitingNCT06364904
What this trial is testing

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Who this might be right for
Bladder Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 210
Large-scale testing (Phase 3)Study completedNCT00942331
What this trial is testing

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Who this might be right for
Advanced Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Prostate Carcinoma+10 more
National Cancer Institute (NCI) 506
Testing effectiveness (Phase 2)Active Not RecruitingNCT04953104
What this trial is testing

ARID1A and/or KDM6A Mutation and CXCL13 Expression

Who this might be right for
Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial Carcinoma+29 more
M.D. Anderson Cancer Center 6
Early research (Phase 1)Study completedNCT02443324
What this trial is testing

Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Who this might be right for
Gastric AdenocarcinomaAdenocarcinoma of the Gastroesophageal JunctionNon-small Cell Lung Cancer+2 more
Eli Lilly and Company 175
Testing effectiveness (Phase 2)Active Not RecruitingNCT03093922
What this trial is testing

Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

Who this might be right for
Urothelial CarcinomaLocally AdvancedUnresectable
Memorial Sloan Kettering Cancer Center 32
Large-scale testing (Phase 3)Study completedNCT02426125
What this trial is testing

Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer

Who this might be right for
Urothelial Carcinoma
Eli Lilly and Company 530
Early research (Phase 1)Ended earlyNCT01282333
What this trial is testing

Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

Who this might be right for
Advanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerMetastatic Transitional Cell Cancer of the Renal Pelvis and Ureter+11 more
National Cancer Institute (NCI) 44
Load More Results